MorphoSys (NASDAQ:MOR) Rating Increased to Hold at Zacks Inv

Zacks Investment Research upgraded shares of MorphoSys (NASDAQ:MOR – Get Rating) from a sell rating to a hold rating in a research report report published on Wednesday, Zacks.com reports. According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company’s proprietary portfolio consists of MOR208, MOR202, […]

Related Keywords

Germany , Planegg , Bayern , , Morgan Stanley , Alphacentric Advisors , Morphosys Company Profile Get Rating , Zacks Investment Research , Blackrock Inc , Millennium Management , Quadrant Capital Group , Get Rating , Centric Advisors , Capital Group , Sys Company Profile , Proprietary Development , Partnered Discovery , Morphosys , Nasdaq Mor , Humor , Medical , Upgrade ,